In vitro and in vivo cytochrome P450 3A enzyme inhibition by Aframomum melegueta and Denniettia tripetala extracts
10.1016/j.apjtm.2017.06.006
- Author:
Sunday O. NDUKA
1
;
Mathew J. OKONTA
2
;
Chinwe V. UKWE
2
;
Daniel L. AJAGHAKU
3
Author Information
1. Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University
2. Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria
3. Department of Pharmacology and Toxicology, Nnamdi Azikiwe University
- Publication Type:Journal Article
- Keywords:
CYP 3A;
Cytochrome P450 enzymes;
Enzyme inhibition;
Herbal extracts
- From:
Asian Pacific Journal of Tropical Medicine
2017;10(6):576-581
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the in vitro and in vivo inhibitory effects of two commonly used herbs, Aframomum melegueta (A. melengueta) and Dennettia tripetala (D. tripetala) on CYP 3A enzymes. Methods In vitro inhibition of the enzymes were assessed with microsomes extracted from female albino rats using erythromycin-N-demethylation assay (EMND) method while their in vivo effects were measured by estimating simvastatin plasma concentrations in rats. Pharmacokinetic parameters were determined using non-compartmental analysis as implemented in WinNonlin pharmacokinetic program. Results EMND assay with intestinal microsomes indicated that aqueous extracts of D. tripetala and A. melengueta significantly (P < 0.05) inhibited intestinal CYP 3A activity at both 50 μg and 100 μg concentrations. Petroleum ether extract of D. tripetala and ethanol extracts of A. melengueta inhibited intestinal CYP3A activity at 100 μg but not at 50 μg concentrations. All the extracts showed an in vitro dose dependent CYP 3A inhibition with liver microsomes. In vivo analysis showed that pre-treatment with the extracts enhanced systemic absorption of simvastatin with reductions in metabolizing enzymes activity as indicated in significant increases in maximal concentration, area under curve, area under moment curve and mean resident time of simvastatin (P < 0.05). Conclusions Herbal preparations containing these plants' extracts should be used with caution especially in patients on CYP450 3A substrate medications.
